GlaxoSmithKline Pharmaceuticals Stock: Growth
GLAXO.NSGlaxoSmithKline Pharmaceuticals reported $412.37M in revenue for fiscal 2026, up 2.6% on the prior year, up 5.7% a year on average over up to five years. That makes three years of growth in a row.
Daily figure as of 22 Nov 2026
Growth per Year by Period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 5.7% | 3.6% | 4.8% |
| Revenue per share | 5.7% | 3.6% | 4.8% |
| Earnings | 23.7% | 10.7% | 3.4% |
| Earnings per share | 23.7% | 10.7% | 5.6% |
| Free cash flow | 12.6% | no data | 7.6% |
| Free cash flow per share | 12.6% | no data | 7.6% |
Growth Over Time
Since 2016 earnings grew faster than revenue, 10.7% against 3.6% a year, because the net margin rose from 14.0% to 27.1%. GlaxoSmithKline Pharmaceuticals has made a profit in every fiscal year since 2007. In the quarter to 30 Sep 2026 revenue grew 20.8% on the prior year quarter, after an average of 7.0% in the four quarters before.
Fiscal Years at a Glance
How Revenue and Earnings Grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $170.7M | $59.45M | $25.89M |
| 2008 | $173.53M | $59.08M | $32.75M |
| 2009 | $182.73M | $63.78M | $33.03M |
| 2010 | $205.86M | $54.8M | $51.92M |
| 2011 | $232.11M | $60.49M | $49.42M |
| 2012 | $260.07M | $46.25M | $31.67M |
| 2013 | $285.99M | $60.63M | $29.62M |
| 2014 | $275.67M | $51.97M | $24.07M |
| 2015 | $284.7M | $41.13M | $15.07M |
| 2016 | $289.65M | $40.59M | −$10.05M |
| 2017 | $313.83M | $36.34M | −$7.38M |
| 2018 | $302.79M | $37.84M | $7.49M |
| 2019 | $334.36M | $48.06M | $11.66M |
| 2020 | $345.19M | $10.06M | $36.1M |
| 2021 | $312.86M | $38.65M | $57.59M |
| 2022 | $352.21M | $182.87M | $83.74M |
| 2023 | $348.14M | $65.9M | $47.5M |
| 2024 | $371.38M | $63.66M | $59.43M |
| 2025 | $402.05M | $100.09M | $136.7M |
| 2026 | $412.37M | $111.79M | $104.36M |
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
